Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $45.50.

HRMY has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft cut their price target on shares of Harmony Biosciences from $54.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, September 25th. Needham & Company LLC decreased their price objective on shares of Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday, September 24th. Truist Financial initiated coverage on shares of Harmony Biosciences in a report on Monday, July 21st. They issued a “buy” rating and a $48.00 price target for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a report on Saturday, September 27th. Finally, HC Wainwright dropped their price objective on shares of Harmony Biosciences from $70.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, September 25th.

Harmony Biosciences Trading Up 1.9%

Shares of NASDAQ:HRMY opened at $27.28 on Monday. The company has a current ratio of 3.84, a quick ratio of 3.80 and a debt-to-equity ratio of 0.20. The company has a 50 day moving average of $33.98 and a 200-day moving average of $33.12. Harmony Biosciences has a twelve month low of $26.26 and a twelve month high of $41.61. The firm has a market cap of $1.57 billion, a P/E ratio of 8.80, a P/E/G ratio of 0.33 and a beta of 0.79.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The business had revenue of $200.49 million during the quarter, compared to the consensus estimate of $204.37 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The firm’s revenue for the quarter was up 16.0% compared to the same quarter last year. Harmony Biosciences has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Harmony Biosciences will post 2.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Texas Permanent School Fund Corp boosted its stake in Harmony Biosciences by 28.4% during the 2nd quarter. Texas Permanent School Fund Corp now owns 34,732 shares of the company’s stock worth $1,098,000 after acquiring an additional 7,686 shares during the last quarter. Cim LLC increased its holdings in Harmony Biosciences by 5.7% during the second quarter. Cim LLC now owns 13,641 shares of the company’s stock worth $431,000 after buying an additional 730 shares during the last quarter. State of Wyoming increased its holdings in Harmony Biosciences by 41.2% during the second quarter. State of Wyoming now owns 8,885 shares of the company’s stock worth $281,000 after buying an additional 2,591 shares during the last quarter. Hohimer Wealth Management LLC acquired a new position in Harmony Biosciences during the second quarter worth $261,000. Finally, Nomura Holdings Inc. increased its holdings in Harmony Biosciences by 382.3% during the second quarter. Nomura Holdings Inc. now owns 422,919 shares of the company’s stock worth $13,364,000 after buying an additional 335,237 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.